Wird geladen...
Activity-based protein profiling shows heterogeneous signaling adaptations to BRAF inhibition
Patients with BRAF V600E mutant melanoma are typically treated with targeted BRAF kinase inhibitors, such as vemurafenib and dabrafenib. Although these drugs are initially effective, they are not curative. Most of the focus to date has been upon genetic mechanisms of acquired resistance; therefore,...
Gespeichert in:
| Veröffentlicht in: | J Proteome Res |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5642956/ https://ncbi.nlm.nih.gov/pubmed/27934295 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jproteome.6b00613 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|